All In Biotech

Drug Trial Radar · NCT03662022

Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar

Last checked: Nov 19, 2026Latest source record: Mar 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 144,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

144,000

Actual

Start

Jan 2, 2019

Primary completion

Jan 17, 2023

Study completion Jan 17, 2023

Sponsor

Lead sponsor
Institute of Tropical Medicine, BelgiumAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Damien Foundation; Centre d'Infectiologie Charles Mérieux; Fondation Raoul Follereau; Leiden University Medical Center; L'Institut National de la Santé et de la Recherche Médicale; Genoscreen; Instituto Fernandes Figueira
First posted
Sep 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 2 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a cluster randomized trial on effectiveness of different modalities of Single Double Dose of Rifampicin Post-Exposure Prophylaxis (SDDR-PEP) for leprosy in the Comoros (Anjouan and Mohéli) and Madagascar. The study aims to identify which approach to the selection of contacts for post exposure prophylaxis is most effective to reduce incident leprosy, and to Interrupt ongoing transmission from asymptomatic persons in the process of developing multibacillary leprosy.

Conditions

  • Leprosy

Interventions

  • RifampicinDrug

    Rifampicin will be given in the same way to arms 2, 3 and 4 (weight dependent). Only the strategy of whom to offer PEP differs between the arms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare Effectiveness in Curbing Transmission of Leprosy of Three Different Approaches of Post Exposure ProphylaxisTime frame: 45 months

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Damien Foundation

    Anjouan, Comoros

  • Damien Foundation

    Mohéli, Comoros

  • Fondation Raoul Follereau

    Miandrivazo, Menabe Region, Madagascar

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.